Table 4.
Indirect comparisons between rivaroxaban, dabigatran, and apixaban*
| Outcomes | Relative risk (95% CI) | ||
|---|---|---|---|
| Rivaroxaban v dabigatran | Rivaroxaban v apixaban | Apixaban v dabigatran | |
| Symptomatic venous thromboembolism | 0.68 (0.21 to 2.23) | 0.59 (0.26 to 1.33) | 1.16 (0.31 to 4.28) |
| Clinically relevant bleeding | 1.12 (0.87 to 1.44) | 1.52 (1.19 to 1.95) | 0.73 (0.57 to 0.94) |
| Major bleeding | 1.37 (0.79 to 2.39) | 1.59 (0.84 to 3.02) | 0.86 (0.41 to 1.83) |
| Net clinical endpoint | 0.95 (0.61 to 1.48) | 0.96 (0.66 to 1.40) | 0.99 (0.61 to 1.61) |
*Random effects model, events while receiving treatment.